Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pitavastatin + levothyroxine
- Development stage
- Unknown
- Lead developer
- Kowa
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of pitavastatin, an HMG-CoA reductase inhibitor (statin) used to lower cholesterol levels, and levothyroxine, a synthetic thyroid hormone used to treat hypothyroidism. Pitavastatin is used for primary hyperlipidemia, mixed dyslipidemia, and heterozygous familial hypercholesterolemia. Levothyroxine is used for hypothyroidism. No direct pharmacological interactions have been found between these medications, although observational studies show a higher rate of statin utilization in patients taking levothyroxine.
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)THR (Thyroid hormone receptor)
Beyond the preview
Go deeper on pitavastatin + levothyroxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pitavastatin + levothyroxine.